Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Inside Kathy Hilton’s Christmas pajama party: caviar bumps, champagne vending machines and a mansion full of Housewives - 2New findings suggest atmosphere could exist on exoplanet TOI-561b
- 3A somber Thor is returning for 'Avengers: Doomsday': Watch the dread-filled teaser
- 4Vote in favor of Your Number one BWM Vehicles
- 5IDF continues counterterrorism operations in Gaza Strip, including destroying terror tunnels
- In a first, scientists observe a comet reversing its spin
- From Representative to Business visionary: Private issue Victories
- Feeling wonder every day improves our health. Here’s how to do it.
- Viable Correspondence: Building Solid Connections
- ‘Nahariya get ready’: Banner displaying Hezbollah threat mounted in Tehran’s Palestine Square
- Vote In favor of Your Favored Sort Of Dress
- Figure out how to Guarantee Your Dental Embeds Endure forever
- Shelby County deputies charged with assault, placed on leave
- Cyber Monday streaming deals 2025: Grab the Disney+ Hulu bundle for only $5 and save over 60%
